Direct evidence for a defined covalently PEGylated MGF product is sparse. Several frequently cited papers instead placed native MGF peptide inside PEGDMA hydrogel devices—a different material question.
Evidence at a glance
- A 2014 independent myoblast study reported no apparent proliferative or differentiation effect from the 24-residue MGF E peptide.
- A separate biomaterials paper delivered native MGF from polyethylene-glycol-dimethacrylate microrods for two weeks and reported 1.72 ± 0.23-fold stem-cell migration.
- FDA states that it has not identified human exposure data for PEG-MGF by any route and flags immunogenicity and characterization concerns.
Study record
The negative 2014 study directly challenged widely repeated claims that the isolated MGF E peptide drives myoblast proliferation or delays differentiation. Including a null study is essential for balanced evidence review.
Results in context
The microrod work used PEGDMA as a polymeric delivery matrix and measured release of native peptide by HPLC. The acronym “PEG” in the carrier name does not mean the MGF molecule itself was covalently PEGylated.
FDA’s current compounding safety page states that PEG-MGF may present immunogenicity risk and API-characterization complexity and that no human exposure data were identified. Preclinical carrier studies do not close that gap.
What the evidence cannot establish
Different MGF sequences, carriers and assay systems cannot be pooled automatically.
Cell migration or mouse cardiac findings are not human efficacy outcomes.
The name PEG-MGF does not define PEG size, linkage, site occupancy or molecular distribution.
Sources & editorial method
This article discusses the source records listed below, with the study models and limitations stated alongside the findings. AI-assisted drafting and image generation were used. The reference list identifies the records behind this article; it is not an independent peer review or verification of a supplied catalog lot.
5 linked records are listed in the references below. Read the editorial and AI-assistance policy.
How to interpret this article
Source-checked on 2026-09-02. Null results, sample size, model/population limits, finished-drug scope, regulatory status and product-evidence boundaries are retained. This is not medical advice, a customer case or validation of a catalog lot.
Research-use boundary: Catalog materials discussed on this website are for laboratory research, development and manufacturing use only, not for human or veterinary use. This content is not medical advice and does not provide administration instructions.
Primary records and authoritative sources
- MGF E peptide showed no apparent myoblast effectNull cell and primary muscle-stem-cell study; PMID 24253050.
- MGF peptide delivery from PEGDMA microrodsBiomaterials delivery study using native MGF in a PEGDMA matrix; PMID 24908137.
- Localized MGF E-domain delivery after mouse myocardial infarctionMouse cardiac delivery study using peptide-eluting polymeric microstructures; PMID 25678113.
- Certain Bulk Drug Substances That May Present Significant Safety RisksU.S. FDA. Current compounding safety-information page.
- WADA 2026 Prohibited ListOfficial list prohibits mechano growth factors.
Continue with structured records
Move from this editorial analysis to the product identity, filtered evidence and controlled terminology behind it.
